Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial Medical Dialogues Bureau2 Nov 2019 9:00 AM ISTOut of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and...